Details

Autor(en) / Beteiligte

• Gordon, Kenneth B
• Blauvelt, Andrew
• Papp, Kim A
• Langley, Richard G
• Luger, Thomas
• Ohtsuki, Mamitaro
• Reich, Kristian
• Amato, David
• Ball, Susan G
• Braun, Daniel K
• Cameron, Gregory S
• Erickson, Janelle
• Konrad, Robert J
• Muram, Talia M
• Nickoloff, Brian J
• Osuntokun, Olawale O
• Secrest, Roberta J
• Zhao, Fangyi
• Mallbris, Lotus
• Leonardi, Craig L

Titel

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Ist Teil von

• The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In three phase 3 trials, ixekizumab, an anti–IL-17A monoclonal antibody, was effective in the treatment of patients with moderate-to-severe plaque psoriasis. Adverse events included neutropenia, candida infections, and inflammatory bowel disease. Psoriasis is a chronic inflammatory disease that is mediated by aberrant immune responses and driven by self-perpetuating cytokine networks. 1 , 2 Advances in understanding the pathogenic cytokine network of psoriasis have led to the development of new treatments 3 – 5 that provide greater efficacy in terms of complete skin clearance. 6 – 9 The motivation to completely clear psoriasis plaques from the skin of patients has grown in response to accumulating evidence that residual skin disease can affect a patient’s health-related quality of life 10 – 12 similar to that associated with chronic conditions such as type 2 diabetes. 13 Ixekizumab, a recombinant, high-affinity, humanized, IgG4-κ monoclonal . . .